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Abstract Functional heavy-chain ^imnuinoglobulins lacking 
light chains occur naturally in Camelidae. We now show the 
feasibility of immunising a dromedary, cloning the repertoire of 
the variable domains of its heavy-chain antibodies and panning, 
leading to the successful identification of minimum sized antigen 
binders. The recombinant binders are expressed well in E. coli, 
extremely stable, highly soluble, and react specifically and with 
high affinity to the antigens. This approach can be viewed as a 
general route to obtain small binders with favourable character-
istics and valuable perspectives as modular building blocks to 
manufacture multispecific or multifunctional chimaeric proteins. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The Fv containing the two variable domains (VH+VL) of 
immunoglobulins and engineered fragments thereof (e.g. sin-
gle chain Fv (scFv) [1] or the disulphide stabilised Fv (dsFv) 
[2]) have been considered as the smallest antibody fragments 
with retention of the full antigen binding capacity [3,4]. PCR 
and the development of powerful panning techniques led to 
the generation of large libraries of scFvs from which several 
binders could be selected successfully [5-7]. This strategy to 
obtain binders for a large number of antigens was a major 
breakthrough in molecular biology. However, the application 
of the technique is not straightforward [3]. The cloning of two 
correctly spliced gene fragments (VH+VL) is a difficult step, 
generating a representative library is tedious, and the genetic 
constructs are often unstable in the bacterial host. Also, the 
expression yield, stability and/or functionality of scFv or dsFv 
often turn out to be problematic [8]. 
The work of Ward et al. [9] indicated that binders could be 
readily selected from a pool of cloned spleen VHs from an 
immunised mouse. These isolated VH domains are expected 
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Abbreviations: CDR, complementarity determining region; CRAbs, 
chelating recombinant antibodies; Fab, antigen binding fragment of an 
antibody; Fv, heterodimer of VH and VL; PCR, polymerase chain 
reaction; SDS-PAGE, sodium dodecyl sulphate-poly aery lamide gel 
electrophoresis; VH, heavy-chain variable domain; VHH, variable 
domain of heavy-chain antibodies; VL, light-chain variable domain. 
Substitutions are denoted by the wild type amino acid followed by the 
residue number and the new amino acid 
to bind antigen in absence of VLs. This approach avoids the 
introduction of a peptide linker used in the scFv constructs 
which might create additional problems (e.g. reduced affinity, 
aggregation or proteolytic cleavage) [10]. However, the insol-
ubility of the isolated VH domains expressed in bacteria, and 
their reduced antigen binding affinity relative to the original 
VH-VL combination, posed serious limitations for their use. 
Reshaping the 'VL side' of the human VH to mimic the var-
iable domain of camel heavy-chain immunoglobulins solved 
the solubility problem [11]. The camelisation of the human 
VH was based on the knowledge that Camelidae produce a 
substantial proportion of their functional immunoglobulins as 
homodimers of heavy chains, lacking light chains [12]. The 
variable domains of these heavy-chain antibodies are distin-
guishable from the classical VH domains because they consis-
tently carry important substitutions of otherwise conserved 
amino acids located in the region which is normally covered 
by the VL [13,14]. To distinguish the classical VH domain 
from the variable domains of the camel heavy-chain antibod-
ies we refer to the latter as V H H . 
Randomisation of the third hypervariable loop, the most 
important loop for antigen binding, on a 'camelised human 
VH' led to a synthetic library from which several hapten bind-
ers were selected [15]. Unfortunately, no useful binders against 
proteins (HIV regulatory protein rev, lysozyme) could be re-
trieved from the synthetic camelised human VH library. 
To avoid this shortcoming, we immunised a camel with two 
model antigens and generated a V H H library displayed on 
phage particles. The camel single domain V H H harbours the 
original, intact antigen binding site [4] and is expected to react 
specifically and with high affinity to the antigen so that further 
affinity and specificity improvement is unnecessary. Indeed 
stable, soluble, specific antigen binders with valuable structur-
al properties [4,14], and good affinities (in the range of 
0.2 XlO8 to 2X108 M_ 1) were identified from this library. 
2. Materials and methods 
2.1. Camel immunisation 
The serum of dromedary (Camelus dromedarius) was shown to be 
non-reacting with tetanus toxoid or lysozyme. This dromedary was 
injected with tetanus toxoid (100 μg) and lysozyme (1 mg) according 
to standard immunisation protocols. The blood of the immunised 
animal was collected and the peripheral blood lymphocytes were pre-
pared with Lymphoprep (Nycomed) and stored at —80°C until further 
use. 
2.2. mRNA isolation, and PCR amplification 
mRNA from approximately 107 peripheral blood lymphocytes was 
isolated and used as template for cDNA synthesis (Micro-FastTrack 
Kit and cDNA Cycle Kit, Invitrogen). The 5' part of the immuno-
globulin heavy chains was amplified by PCR with two gene-specific 
primers: VHBACKA6: 5'-GAT GTG CAG CTG CAG GCG TCT 
GG(A\G) GGA GG-3' and CH2FORTA4: 5'-CGC CAT CAÁ GGT 
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ACC AGT TGA-3'. From these PCR products we reamplifled the 
VHH gene with VHBACKA4: 5'-CAT GCC ATG ACT CGC GGC 
CCA GCC GGC CAT GGC CGA (GYT)GT (G\C)CA GCT-3' and 
VHFOR36: 5'-GG ACT AGT GCG GCC GCG TGA GGA GAC 
GGT GAC CTG-3' containing Sfil and NotI restriction enzymes sites 
(underlined). The resulting PCR fragments of 450-520 bp were puri-
fied from agarose by Geneclean (Bio 101, Inc.), digested with Sfil and 
Notl, and purified again by Geneclean. 
2.3. Library construction 
The vector (pHENl) [16] was modified by introducing a new clon-
ing site to insert the camel VHH gene and by substitution of the c-myc 
tag with the decapeptide HA-tag [17] (referred to as pHEN4). The 
pHEN4 phagemid (10 μg), digested with Sfil and Notl and gel-puri-
fied, was liga ted overnight at 16°C with T4 DNA ligase (Boehringer 
Mannheim) to the PCR fragments (5 μg). 
The ligated material was transformed into ultracompetent XL2-Blue 
MRF cells (Stratagene), and the cells were plated on LB-ampicillin 
agar plates. The colonies were scraped from the plates with 2XTY-
ampicillin, and stored in 2xTY, 1% glucose, 50% glycerol at — 80°C 
until further use. E. coli XLl-Blue MRF cells were made electrocom-
petent and transformed with a second batch of ligated material to 
generate the second library. 
2.4. Preparation of phage and selection of tetanus toxoid or lysozyme 
binders 
Approximately 109 cells were grown to mid-logarithmic phase be-
fore infection with M13K07. Virions were prepared as described by 
Kang et al. [18], and used for panning at a titre of 1013/ml. For 
panning, we coated the microtitre wells (Nunc, Maxisorp) overnight 
at 4°C with 100 μΐ tetanus toxoid (0.25 mg/ml in PBS). For lysozyme 
coating was performed at 3 mg/ml for the first round and at 1 mg/ml 
for subsequent pannings. The wells were blocked (PBS+1% casein) 
at 37°C for 1 h. The adsorption of virions on immobilised antigen 
and the washing and elution of binders with 50 mM diethylamine 
were carried out according to Marks et al. [19]. Phages eluted after 
each round of panning were added to exponentially growing TGI cells 
[16] and plated on LB-ampicillin. The enrichment was evaluated by 
testing 96 individual clones by ELISA (coating solutions of tetanus 
toxoid or lysozyme at 5 μg/ml). The presence of the virion binding 
was revealed by anfi-M13/Horse Radish Peroxidase conjugate (Phar-
macia). 
2.5. Preparation of soluble VHH fragments 
The vector DNA from selected positive clones was transformed into 
the non-suppressor strain of E. coli (WK6). The WK6 cells harbouring 
the recombinant phagemids were grown at 37°C in 300 ml TB-ampi-
cillin, 1% glucose in culture flasks until OD550 0.5. The cells were 
washed and resuspended in 300 ml TB-ampicillin, induced with 
IPTG (1 mM), and incubated overnight at 28°C. The periplasmic 
proteins were extracted according to Skerra et al. [20]. The periplas-
mic extracts were concentrated ten-fold by ultrafiltration (Millipore, 
cut-off 5000 Da). The concentrated extracts of the two tetanus toxoid 
binders (cAb-TTl or cAb-TT2) were separated by gel filtration 
on Superdex-75 (Pharmacia) in PBS. One of the lysozyme bind-
ers (cAb-Lys3) was purified by affinity chromatography on a lyso-
zyme-Sepharose column. After washing with PBS, the bound single 
domain antibody fragments were eluted with 50 mM diethylamine, 
neutralised and subsequently passed over Superdex-75 (Pharmacia) 
in PBS buffer. The second lysozyme binder (cAb-Lys2) was purified 
by a protein A-Sepharose affinity chromatography followed by gel 
filtration. 
2.6. Determination of affinity, specificity and epitope mapping 
Affinity was determined by competitive ELISA [21]. The bound 
camel VHH fragment was detected with a mouse antibody specific 
for the Hemagglutinin Tag (clone 16B12, BAbCO, California) or 
with polyclonal rabbit anti-camel IgG antibodies. 
Specificity of VHH fragments was examined by ELISA [22]. The 
non-related immunogens included casein, globular part of histone 
H5, BSA, RNase Tl, Arcelin-5, concanavalin A, phytohaemaggluti-
nin, Pseudomonas aeroginosa lipopolysaccharides, tetanus toxoid (for 
lysozyme binders) and lysozyme (for tetanus toxoid binders). 
Binding to individual or overlapping epitopes was assessed accord-
ing to Friguet et al. [22]. 
Fig. 1. Agarose gel electrophoresis of VHH amplification products 
with VHBACKA6 and VHFORTA4 on camel lymphocyte cDNA 
(lane 2), and with VHBACKA4 and VHFOR36 on DNA of lane 2 
(lane 3). Lanes 1 and 4: 123 bp ladder size marker. The sizes (in 
bp) are indicated for the marker (thin lines) and PCR products 
(thick lines). 
3. Results 
3.1. PCR amplification of camel V¡¡Hs 
We used 107 peripheral blood lymphocytes from a drome-
dary immunised simultaneously with tetanus toxoid and lyso-
zyme, to extract mRNA from which cDNA was synthesised. 
The VH and V H H regions were amplified by nested PCR. In 
the first PCR, the VHBACKA6 primer is based on available 
protein sequence information and on the camel V H H clone 
cVH2 [13]. This primer is predicted to anneal to codons 1 
to 10 of the camel V H H of subgroup III, the only family 
reported to be present in camels [13]. The CH2FORTA4 pri-
mer hybridises in the CH2 region of camel g-immunoglobulin 
mRNA [12]. The resulting PCR fragments have distinct sizes 
around 620, 690 and 900 bp (Fig. 1). We infer that these PCR 
products are derived from the homodimer heavy-chain anti-
bodies with short and long hinges and from the heavy chains 
of the classical heterotetramer immunoglobulins [12]. In a 
second PCR, we reamplifled the VH and V H H part of these 
fragments with a VHBACKA4 primer containing a Sfil and a 
VHFOR36 primer containing a Notl site for cloning purposes. 
The VHFOR36 primer anneals to the framework 4 region. 
This nested PCR generated a single broad band between 
450-520 bp in length (Fig. 1). 
3.2. Camel VHIVHH library 
After Sfil and Noil digestion, we ligated the purified PCR 
fragments into pHEN4 (a modified pHENl vector [16]), be-
tween the PelB leader signal and the gene III. The ligated 
DNA material was used to transform E. coli XL2 Blue 
MRF' cells, and approximately 500000 individual recombi-
nant clones were obtained. A second batch of ligated material 
was transformed in electrocompetent E. coli XL1 Blue MRF 
cells. The second library contained 107 individual clones. Col-
ony screening by PCR showed that 90% of the clones con-
tained a plasmid with an insert of the expected size for a 
camel V H H gene. The heterogeneity of the individual clones 
from the libraries was checked by sequencing the CDR3 part 
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Fig. 2. Amino acid sequences of tetanus toxoid (cAb-TTl and cAb-
TT2) and lysozyme binders (cAb-Lys2 and cAb-Lys3). The Kabat 
et al. [23] numbering is used, the specific VHH amino acids are 
thick-lined boxed, the CDRs are thin-lined boxed. 
two tetanus toxoid and the two lysozyme binders reveals that 
different V H H germline genes were used. Furthermore, the 
CDR3's with lengths of 10, 18, 19 and 24 amino acids, do 
not share any sequence similarity. Three of the four clones 
contain a cysteine in the CDR3 which could possibly form a 
disulphide bond with a second cysteine located in the CDR1, 
or with a second cysteine at position 45 in the case of the anti-
tetanus toxoid V H H fragment of ρΗΕΝ4-αΤΤ1. We inserted a 
position 26a (Fig. 2) to improve the sequence alignment of 
this clone with other VHs. 
3.5. Production of soluble, monomeric camel VHHS 
The four DNA phagemids of the isolated clones were trans-
formed into WK6 cells. These cells are unable to suppress the 
amber stop codon between the cloned V H H and the gene III, 
and will produce soluble V H H fragments upon induction with 
of the cloned insert. Each clone contained a different CDR3 
sequence. 
3.3. Phage selection 
The small libraries was panned separately for the presence 
of tetanus toxoid or lysozyme binders. A total of approxi-
mately 3 X 1011 phages were used in each round of panning. 
For tetanus toxoid, we eluted 2X 105, 1.5 X 106, 1.7 X106, and 
1.2 XlO7 phages after the first, second, third, and fourth 
round of panning, respectively. The phage titre of the non-
specific binders from wells without antigen remained constant 
(4-6 XlO4). 
To evaluate the enrichment during the pannings with teta-
nus toxoid, we prepared virions from 96 randomly chosen 
colonies after each round of panning and tested their binding 
to tetanus toxoid. In the original library we found 1 clone out 
of 96 bound to the immobilised tetanus toxoid. This number 
was increased to 11, 48, 80 and 95 after the first, second, third 
and fourth round of panning, respectively. 
A DNA fragment of V H H size was amplified by PCR on 
twenty individual positive clones from the final round of pan-
ning. According to small migration differences on acrylamide 
gels the inserts were grouped into two classes. Sequencing 
confirmed the presence of two different clones. The DNA 
phagemids of these clones were referred to pHEN4-oeTTl 
and pHEN4-ccTT2, (BCCM/LMBP; accession number 
LMBP3247). 
Surprisingly, no lysozyme binder was extracted from this 
small library. The possibility remains that the size or complex-
ity of the smaller library was insufficient. Indeed, following 
the same procedure, we succeeded in selecting two lysozyme 
binders from the second library of 107 individual clones. 
These DNA phagemids were named pHEN4-Lys2 and 
pHEN4-Lys3. Immobilising the C-fragment of tetanus toxin 
during the pannings, lead to the isolated of the pHEN4-otTTl 
from this library. No other binders to the C-fragment of tet-
anus toxin were obtained. 
3.4. VgH sequences 
The amino acid sequences 
cial substitutions Leu 11 Ser, 
(or Cys), and Trp47Gly (or 
[23]). These substitutions of 
are hallmarks of VHHS origi 
dimer immunoglobulins [13] 
of all four binders have the cru-
Val37Phe, Gly44Glu, Leu45Arg 
Leu) (Fig. 2) (Kabat numbering 
otherwise conserved amino acids 
inating from heavy-chain homo-
The sequence information of the 
Fig. 3. A: SDS-PAGE of periplasmic extract from IPTG induced 
WK6 cells harbouring ρΗΕΝ4-αΤΤ1 (lane 2), purified fraction of 
cAb-TTl (lane 3), periplasmic extract of WK6 with pHEN4-aTT2 
(lane 4) and purified fraction of cAb-TT2 (lane 5). Lane 1 is a MW 
marker (sizes in kDa are indicated). B: Gel filtration of the cAb-
TT2 periplasmic extract followed by absorbance at 280 nm (thin 
line). The tetanus toxoid binding activity of each fraction was meas-
ured in ELISA (bold line). An absorbance around 0.1 at 405 nm 
was measured in wells without tetanus toxoid coating, or without 
addition of cAb-TT2. The fractions 30-35 contain the monomeric 
cAb-TT2, whereas fractions 26-29 contain the proteins with MW 
around 35000. 
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Fig. 4. A: Specificity of the soluble cAb-TTl and cAb-TT2 (respec-
tively white and black rectangles at the left), or cAb-Lys2 and cAb-
Lys3 (white and black rectangles respectively at the right) as deter-
mined by ELISA. See Section 2 for a list of the 'unrelated antigens' 
used (differences among the different unrelated antigens were negli-
gible). B: Affinity of different cAbs measured according to Friguet 
et al. [21]. C: Antigen binding activity of the different cAbs meas-
ured after up to 200 h incubation at 37°C. The experimental condi-
tions were those reported by Reiter et al. [2], and for reference we 
included their data of the B3 scFv and dsFv. 
IPTG. The camel single domain V H H binders are referred to 
as cAb. 
The expressed proteins were extracted from the periplasmic 
space and visualised by Coomassie blue staining on SDS-
PAGE. Protein bands with apparent MW between 16000 to 
18000 were clearly present in the induced E. coli cultures 
containing the recombinant DNA (Fig. 3A). The same pro-
teins were detected by Western blot using a specific rabbit 
anti-dromedary IgG serum or with an anti-decapeptide tag 
antibody (data not shown). 
The expressed cAbs constitute already a large part of the 
proteins present in the periplasmic extract. Further enrich-
ment of the soluble cAb-TTl or cAb-TT2 was achieved by 
gel filtration on Superdex-75. The single peak containing the 
anti-tetanus toxoid activity eluted at the expected MW of 
16000 indicating that the protein behaves as a monomer 
and does not dimerise in solution (Fig. 3B). 
The anti-lysozyme cAbs were produced with a similar yield. 
Here the purification was performed by affinity chromatogra-
phy on protein A-Sepharose for the cAb-Lys2 and on a lyso-
zyme-Sepharose column for the cAb-Lys3. Of all the identified 
cAbs, only the cAb-Lys2 binds to the protein A-Sepharose 
column. This is somewhat surprising as most mammalian 
VHs of family III, to which the camel VHHS belong, are 
recognised by protein A [24]. The purification of the cAb-
Lys2 on the lysozyme-Sepharose affinity chromatography 
was abandoned as it eluted from the column only under harsh 
conditions. 
The fractions containing the pure cAbs were pooled. From 
the absorption measurement at 280 nm, a yield in the range of 
3 to 6 mg of purified protein per litre of bacterial culture 
(ODeoonm = 12) was calculated. The purified protein was con-
centrated by ultrafiltration up to 10 mg/ml in PBS or water 
without any sign of aggregation. 
3.6. Specificity, affinity and stability 
The specificity of the soluble cAb-TTl, cAb-TT2 and of 
cAb-Lys2, cAb-Lys3 was suggested from the ELISA experi-
ments in which binding was competed with free tetanus toxoid 
or free lysozyme. Also, no cross-reactivity could be detected in 
a direct ELISA experiment with several other unrelated im-
mobilised antigens (Fig. 4A). 
The affinity constant, measured accurately by ELISA [21], 
was found to be 6 x l 0 7 M" 1 and 3 x l 0 7 M" 1 for the cAb-
TT1 and cAb-TT2, respectively. The anti-lysozyme cAb-Lys2 
and cAb-Lys3 have an affinity of 2Xl0 7 and 2Xl0 8 M"1 , 
respectively (Fig. 4B). 
To test the stability of the cAbs, we followed the procedure 
of Reiter et al. [2] in which the remaining antigen binding 
activity of the purified antibody fragments was determined 
after different incubation times in PBS at 37°C. These authors 
analysed the B3 scFv and the B3 dsFv over an incubation 
period of 60 h. This particular scFv lost all its funtionality 
after 24 h, whereas the dsFv retained 60% of its maximal 
antigen-binding capacity after 60 h of incubation [2]. In con-
trast, under these conditions the purified camel V H H frag-
ments retained between 80 and 100% of their original antigen 
binding activity (Fig. 4C). Moreover, the incubation could be 
prolonged for up to 200 h without further reducing the lyso-
zyme or tetanus toxoid binding. Therefore the superposition 
of the data reported by Reiter et al. [2] for the B3 scFv and 
the B3 dsFv on our cAb data (Fig. 4C) proves that for these 
conditions the stability of all the cAbs is largely superior to 
that of the B3 scFv or dsFv [2]. 
3.7. Epitope mapping 
Tetanus toxin consists of three domains, named A, B, and 
C [25]. We showed by ELISA that the cAb-TTl extract binds 
equally well both to the complete tetanus toxoid and to the 
recombinant C fragment (Fig. 4A). Therefore, the epitope of 
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this camel V H H is present on the C fragment. In contrast, the 
cAb-TT2 extract binds to the complete tetanus toxoid, but not 
to the recombinant C fragment, suggesting that cAb-TT2 rec-
ognises an epitope located on the A or B domain (Fig. 4A). 
An ELISA additivity experiment [22] confirmed that separate 
epitopes on the tetanus toxoid are recognised (additivity index 
of 43%). 
The anti-lysozyme-specific cAbs were also subjected to an 
ELISA additivity test. Here the measured additivity index was 
58%, which is decisive for binding to two different epitopes on 
lysozyme [22]. 
4. Discussion 
The presence of naturally occurring and functional homo-
dimer heavy-chain immunoglobulins in camelidae sera [12] 
indicated that isolated camel VHHS would be more soluble 
than their mouse or human equivalents. The important amino 
acid substitutions of otherwise conserved amino acids in the 
'former' VL and CHI sides found in the camel heavy-chain 
V H H domains supported this view [13]. Indeed, introducing 
these substitutions improved the folding and solubility of iso-
lated human VHs [11,15]. 
In this study we tested the feasibility to identify single do-
main antibody fragments (VHH) against two proteins, namely 
tetanus toxoid and lysozyme. The first antigen was chosen 
because it is a immunogenic protein [26] that is routinely 
used as a vaccine in humans. The results of the selected camel 
V H H might therefore be compared to the human anti-tetanus 
toxoid Fabs [17,26]. The availability of abundant detailed 
structural knowledge of the anti-lysozyme antibodies [27] 
was the major reason for choosing the second antigen. 
Libraries containing the variable region repertoire of heavy 
chains from immunised camel blood lymphocytes, were con-
structed. The libraries were panned separately against tetanus 
toxoid and lysozyme. After four rounds of panning with tet-
anus toxoid or lysozyme we retrieved each time two clones 
binding to different epitopes on the antigen. The amino acid 
sequences of all four binders are consistent with the camel 
VHHS. Apparently different V H H germline and D minigenes 
were used in the VDJ recombination. This indicates that a 
sufficiently large repertoire of minigenes lies at the origin of 
the camel heavy-chain antibody generation. We are therefore 
confident that other immunogens can also be used to select 
camel single domain binders. 
The yield of the purified cAb-TT2 reaching 6 mg per litre of 
bacterial culture is on a molar basis comparable or even better 
than most scFv or Fab expressions obtained in E. coli. Since 
three of our four clones under study possess Gly47, it can be 
inferred from the work of Davies and Riechmann [15] that the 
expression yield might even increase by a Gly47Ile substitu-
tion. Furthermore, the solubility of cAb-TT2 at 10 mg/ml is 
certainly higher than that of isolated mouse VH fragments. 
We also indicated the strictly monomeric nature of the VHHS. 
The yield and solubility are well within the range needed for 
most applications. 
A striking feature of the cAbs is their capacity to withstand 
prolonged incubation at 37°C. cAb-TT2 is slightly less stable, 
possibly due to the absence of a disulphide bond between its 
CDRs. Indeed, the importance for stability of the extra disul-
fide bond in the camelised human VH fragments was shown 
by thermal denaturation [28]. 
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The cAb affinities in the range of 0.2 to 2X 108 M _ 1 com-
pare favourably with those of human anti-tetanus toxoid Fab 
fragments (107—109 M_ 1) [17,26] or mouse anti-lysozyme 
scFvs D1.3 and HyHEL-10 (1.4X106 and 3.0X108 M"1 re-
spectively) [29]. Probably the high affinity and specificity of 
cAb for a large antigen comes predominantly from the long 
CDR3 loop which provides a sufficiently large antigen binding 
surface able to insert into clefts of the antigen. In the crystal 
structure of the cAb-Lys3:: lysozyme complex [14] the CDR3 
protrudes from the remaining antigen binding site and is in-
deed inserted in the cleft of the catalytic site of the enzyme. 
Consequently, the absence of the VL domain in camel heavy-
chain antibodies does not compromise their affinity or speci-
ficity. Moreover, the generation of specific camel VHHS might 
be an adequate strategy to develop enzyme or receptor inhib-
itors [4]. 
It might be argued that a library of a camelised human VH 
topped with a long synthetic CDR3 might be used to generate 
small molecular recognition units. This strategy is similar to 
the one we describe here and has the advantage that it by-
passes the dromedary immunisation. However, it should be 
noted that these synthetic antibody fragments are not matu-
rated in vivo like the natural camel antibodies, and so the 
camelised single domain VHs might require additional engi-
neering, especially in the CDR1 and CDR2, to improve their 
affinities [29]. Secondly, although this method was successful 
for the generation of hapten binders, only poor binders to 
protein antigens could be retrieved from the synthetic library 
of a camelised human VH [15]. Possibly, the long and uncon-
strained synthetic CDR3 loop which becomes immobilised 
upon antigen interaction has a counterproductive entropic 
effect on binding. In contrast, the long CDR3 loop of the 
cAb-Lys3 showed considerable internal structure to stabilise 
and constrain the loop even in the uncomplexed form [14]. 
Considering the single domain nature of the cAbs, it should 
be straightforward to construct small bivalent or even multi-
valent binders, or CRAbs [30] in order to increase their avid-
ity. Also, the generation of bispecific constructs can be envis-
aged to broaden the potential applications of camel single 
domain antibodies [31]. In all cases the resulting molecules 
will always be simpler, smaller, and probably more stable 
than the corresponding derivatives of scFvs or Fabs. 
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